Related by context. All words. (Click for frequent words.) 66 UPDRS motor 65 WOMAC pain 64 ADAS Cog 64 nasal symptom 64 ADCS CGIC 64 DLQI 63 PANSS total 62 BMI z 61 Postoperatively 61 biopsy Gleason 61 SGRQ 61 Montgomery Åsberg Depression 61 Severity Index PASI 61 non menstrual pelvic 61 clinically meaningful improvement 61 IBDQ 61 NIHSS 61 HDRS 61 demonstrated clinically meaningful 60 Secondary endpoints included 60 ADAS cog 60 GERD symptom 60 CNS LS 60 Global Impression CGI 60 QIDS SR 60 Primary endpoints 60 liver histology 60 baseline PASI 60 clinically meaningful improvements 59 ALIMTA cisplatin 59 haematologic 59 carotid IMT 59 Secondary endpoints 59 clinically meaningful reductions 59 Scale EDSS 59 Fibromyalgia Impact Questionnaire 59 preoperative PSA 59 Brief Psychiatric 59 serum phosphorous 59 Index CDAI 59 Psoriasis Area 59 EDSS 59 neurocognitive function 59 phase IIb study 58 PASI scores 58 Montgomery Asberg Depression 58 DAS# CRP 58 Inventory BPI 58 Status Scale EDSS 58 Crohn Disease Activity 58 Rating Scale MADRS 58 achieved statistical significance 58 subthreshold depression 58 morphometric vertebral fractures 58 Neuropsychiatric Inventory 58 methacholine challenge 58 dyspareunia 58 Ishak fibrosis score 58 deep venous thromboses 58 Health Assessment Questionnaire 58 EQ 5D 57 N telopeptide 57 Secondary efficacy endpoints 57 QoL 57 Visual Analog 57 AUA Symptom Score 57 #.#ng/ml 57 NYHA functional class 57 postoperative complication 57 Secondary endpoints include 57 APACHE II 57 brachial artery flow 57 rosuvastatin #mg 57 somatic symptom 57 relapsed MM 57 IKDC 57 HRQL 57 preintervention 57 aminotransferases 57 postoperative AF 57 Y BOCS 57 mediated dilation 57 Erectile function 57 MoxDuo TM IR 57 #mg dose [002] 57 opioid naïve 57 genotypic resistance 57 hemoglobin A1c levels 57 alanine aminotransferase ALT 57 aminotransferase ALT 57 Preoperatively 57 intact parathyroid hormone 57 surgically induced 57 Negative Syndrome 57 prespecified secondary 57 gross hematuria 57 cardiorespiratory endurance 57 achieved ACR# 57 nicardipine 57 PANSS scores 57 Visual Analogue Scale VAS 57 psychosocial functioning 57 intima media thickness 57 abnormal ejaculation 56 glycosylated hemoglobin levels 56 extracapsular extension 56 bone marrow reticulin deposition 56 Coronary artery calcium 56 CINQUIL 56 prospectively stratified 56 attain statistical significance 56 Alzheimer Disease Assessment 56 indicates cardio circulatory 56 intravascular hemolysis 56 erection hardness 56 PSA nadir 56 Scale PANSS 56 PANSS 56 dactylitis 56 HRQoL 56 preoperatively 56 myocardial reperfusion 56 CPAP adherence 56 YMRS 56 obstructive CAD 56 oxycodone CR 56 teriflunomide 56 reactogenicity 56 IELT 56 Scale cognitive subscale 56 MMSE score 56 Visual Analog Scale 56 NIH CPSI 56 prednisone prednisolone plus 56 aspartate aminotransferase AST 56 epoetin alpha 56 Symptom severity 56 Index CDAI score 56 hematological parameters 56 aspartate aminotransferase 56 SELENA SLEDAI 56 BPH symptom score 56 tipranavir r 55 HER2 expression 55 #ng/ml 55 orthostatic blood 55 F FDG PET 55 analgesic efficacy 55 alfuzosin 55 CCyR 55 lumbar spine BMD 55 nadroparin 55 tissue oxygenation 55 alicaforsen enema 55 Atkins dieters cardiovascular 55 hepatic lesions 55 lopinavir r arm 55 glycosylated hemoglobin HbA1c 55 subjective sleepiness 55 HAM D# 55 colorectal adenoma 55 posttreatment 55 serum aminotransferase levels 55 lactate dehydrogenase 55 sonographically guided 55 symptom severity 55 intraobserver 55 knee extensor 55 #mm Hg 55 specific antigen PSA 55 QTcF 55 depressive symptom 55 exploratory endpoints 55 endometrial thickness 55 postdose 55 Subgroup analysis 55 hepatic enzyme 55 Ashworth Scale 55 AST ALT 55 Negative Symptoms 55 CC genotype 55 1mg dose 55 plasma triglycerides 55 Ceplene/IL-2 55 paricalcitol 55 hsCRP levels 55 hip BMD 55 premenopause 55 Histologic 55 spine BMD 55 decompensated cirrhosis 55 elevated ALT 55 abacavir lamivudine 55 CIMZIA TM certolizumab pegol 55 virologic responses 55 WOMAC 55 bunion deformity 55 fasting plasma glucose FPG 55 transdermal estradiol 55 vasomotor symptoms 55 HAQ DI 55 Severity MSCS score 55 invasive carcinomas 55 EDEMA3 trial 55 p = .# [002] 55 parkinsonian symptoms 55 femoral neck BMD 55 Known hypersensitivity 54 pT3 54 baseline Hb 54 left ventricular diastolic 54 microbiological eradication 54 preterm neonates 54 â ‰ ¥ 54 fructosamine 54 ventricular tachyarrhythmia 54 erythrocyte sedimentation rate 54 Tasigna prolongs 54 CYP#D# inhibitor 54 coronary calcification 54 Stroke Scale NIHSS 54 HBeAg negative patients 54 serum lipid levels 54 cardiac repolarization 54 confirmed CCyR 54 glomerular filtration 54 #.#/#.# mmHg [001] 54 urine albumin 54 P ≤ 54 FUSILEV enhances 54 scintigraphic 54 Disease Activity 54 mm Hg diastolic 54 ginkgo extract 54 plasma folate 54 Coronary angiography 54 transaminase elevations 54 bronchial hyperresponsiveness 54 desvenlafaxine succinate 54 pharmacokinetic PK profile 54 WOMAC scores 54 MMSE scores 54 PLX STROKE targeting 54 systemic hypotension 54 confidence interval #.#-#.# 54 Lumbar spine 54 LV ejection fraction 54 #mg ATC 54 hemodynamic measurements 54 diastolic blood pressures 54 Xelox 54 hemodynamic parameters 54 infliximab monotherapy 54 6MWD 54 receiving XGEVA 54 hyperphenylalaninemia HPA due 54 occluded catheters 54 abnormal cytology 54 ARB telmisartan 54 MCyR 54 CIN2 + 54 carotid intima media 54 Seattle Angina Questionnaire 54 oncologic outcomes 54 Rating Scale BPRS 54 tapentadol ER 54 nonsignificant difference 54 #mmHg [001] 54 extrapyramidal symptoms 54 XIENCE V PROMUS Stent 54 posttest 54 intravascular ultrasonography 54 grade squamous intraepithelial 54 aromatase inhibitor therapy 54 cytogenic 54 perioperatively 54 analgesic medications 54 NMIBC 54 histologically proven 54 OSDI 54 Endothelial function 54 ejection fractions 54 subscales 54 International Prostate Symptom 54 LH FSH 54 refractory ischemia 54 achieved CCyR 54 blood Phe levels 54 intima media thickness IMT 54 bezafibrate 54 protein excretion 54 Epworth Sleepiness Scale 54 systemic corticosteroid 54 NNRTI resistance 54 euthymic patients 54 Score DAS 54 ankle brachial index 54 postprocedure 54 coagulation parameters 54 Doxil ® 54 plasma creatinine 54 elevated IOP 54 Doppler echocardiography 54 DCE MRI 54 postintervention 54 methotrexate monotherapy 53 serum urate 53 multivariate Cox 53 NIS LL 53 transdermal testosterone patch 53 carotid artery blockage 53 overnight polysomnography 53 recovery CRp 53 carotid artery intima media 53 zonisamide SR 53 urodynamic 53 nondiabetic patients 53 adnexal masses 53 pulmonary capillary wedge 53 DEXA scans 53 steroid dexamethasone 53 nonobese 53 abnormal lipid 53 % CI #.#-#.# [003] 53 #q# deletion syndrome 53 FDG-PET/CT 53 pentoxifylline 53 intravenous cyclophosphamide 53 mRS 53 urinary N telopeptide 53 uteruses authorities 53 lesional 53 hepatic enzymes 53 dehydroepiandrosterone sulfate 53 underwent coronary angiography 53 histologic 53 Univariate analysis 53 creatine kinase 53 HIV HCV coinfected 53 serum PSA 53 axillary lymph node 53 IRLS 53 anemia hemoglobin 53 FFNS 53 Fasting glucose 53 lipid parameters 53 levosimendan 53 microalbumin test 53 atrial pacing 53 NNT = 53 HOMA IR 53 invasive angiography 53 IRLS score 53 comorbid anxiety 53 ascending aortic 53 CDAI 53 REYATAZ r arm 53 clomipramine 53 P = .# 53 UPDRS 53 thermoplasty treated 53 apolipoprotein A1 53 hemostatic efficacy 53 transabdominal 53 CIMZIA ™ 53 folinic acid 53 inhaled iloprost 53 Bone density 53 Neuropsychiatric Inventory NPI 53 LDL triglycerides 53 androgen ablation 53 pretransplant 53 abnormal clotting 53 complete cytogenetic response 53 nodal metastasis 53 pyridostigmine 53 Myocardial Infarction TIMI 53 hematologic abnormalities 53 biochemical recurrence 53 fasting insulin 53 cough dyspnea 53 HRQOL 53 hemodynamically significant 53 postural sway 53 myocardial perfusion 53 interobserver 53 multivariable adjusted 53 HoLEP 53 sumatriptan naproxen sodium 53 somatostatin analog 53 fluticasone salmeterol 53 EUFLEXXA R 53 glycated hemoglobin levels 53 nasal lavage 53 nitroprusside 53 -#.# log# copies mL 53 x ULN 53 ADHD Rating Scale 53 neutropenic sepsis 53 postoperative delirium 53 adenotonsillectomy 53 statin monotherapy 53 apolipoprotein B 53 pancreatic prostate 53 posttransplant 53 PSQI 53 non squamous histology 53 mucosal healing 53 troponin T 53 State Examination MMSE 53 trials RCTs 53 Intravitreal 53 tertile 53 statistically significant efficacy 53 serum cortisol 53 thinner struts 53 coronary stenosis 53 trastuzumab Herceptin ® 53 interobserver reliability 53 DAS# scores 53 deCODE ProstateCancer TM 53 esophagogastric 53 elevated creatinine 53 SSRI SNRI 53 Unified Parkinson Disease 53 Efficacy endpoints 53 CDAI score 53 mTSS 53 serum testosterone 53 atorvastatin #mg 53 carotid bruit 53 coronary artery calcification 53 duplex ultrasonography 53 lactate dehydrogenase LDH 53 neoplasias 53 CK MB 53 Likert pain 53 nonmetastatic 52 nonfatal MI 52 recurrent atrial fibrillation 52 T2 lesions 52 glycated hemoglobin HbA1c 52 Description Enhance 52 HAMD 52 MDCT angiography 52 MyoCell SDF 1 52 urine cytology 52 BPH Symptom Score 52 corticosteroid dose 52 pCR 52 catheter occlusion 52 azilsartan medoxomil 52 assessing T DM1 52 Glasgow Coma Scale 52 OAB symptoms 52 statistically significant superiority 52 Non inferiority 52 Breslow thickness 52 ACAPODENE 52 Coronary calcium 52 edifoligide 52 undetectable viral 52 plasma adiponectin 52 artery stenosis 52 mL/min/#.# m 2 52 calculated creatinine clearance 52 hydroxyvitamin D levels 52 treated nonoperatively 52 pre operatively 52 electrophysiologic 52 Skin sterol 52 BEXXAR Therapeutic Regimen 52 perioperative morbidity 52 multivariable analyzes 52 catheter ablations 52 postinjury 52 Pfizer reanalyzed 52 interferon beta therapy 52 Global Impression 52 elective PCI 52 lumbar spine bone 52 poststroke 52 histopathological 52 mineral density BMD 52 liposomal doxorubicin 52 bronchoalveolar 52 Fasting plasma glucose 52 peak VO2 52 Key secondary endpoints 52 daytime alertness 52 LV dysfunction 52 DAS# [002] 52 transesophageal 52 advanced adenomas 52 BCG vaccinated 52 subscores 52 Dodge Avenger Nissan Altima 52 hematopoietic cancers 52 serum lipid 52 fatigue abdominal pain 52 -#.# mg dL [001] 52 symptomatic VTE 52 PRADAXA #mg 52 carotid endarterectomy CEA 52 Prostate specific antigen 52 diastolic pressures 52 transthoracic 52 MS relapses 52 Qmax 52 IOP lowering 52 Mean Symptom Complex 52 C telopeptide 52 diabetic kidney 52 intracerebral haemorrhage 52 perineural invasion 52 diameter stenosis 52 pharmacokinetic characteristics 52 semiquantitative 52 DAS# remission 52 invasive lobular 52 quantitative coronary angiography 52 nighttime awakenings 52 serum thyroglobulin 52 pharmacodynamic properties 52 EDSS scores 52 Stroke Scale 52 leucopenia 52 mmHg systolic 52 aspirin clopidogrel 52 hypofractionated radiation 52 Bonferroni correction 52 cardiac perfusion 52 renal artery stenting 52 dose proportionality 52 tumor histology 52 permanently discontinue Vectibix 52 % CI #.#-#.# [007] 52 Oswestry Disability Index 52 ecchymosis 52 Vascugel ® 52 echocardiographic parameters 52 CrCl 52 serum urate levels 52 neuritic 52 #.#mg/dL 52 inotropic 52 Visual Analogue Scale 52 hormone receptor negative 52 rhinoconjunctivitis 52 stratifying patients 52 neurologic outcomes 52 Achieves Primary Endpoint 52 bortezomib refractory 52 baseline serum creatinine 52 locomotor activity 52 KOOS 52 HbA1C levels 52 postoperative morbidity 52 obstructive coronary 52 SpO2 pulse rate 52 elevated transaminases 52 receiving golimumab 52 serum parathyroid hormone 52 transaminases 52 prednisone prednisolone 52 ZOLINZA 52 μg d 52 SGOT 52 RAPAFLO R 52 menopausal symptom 52 Coleman Liau 52 calcium antagonists 52 CHADS2 52 FDG uptake 52 ADCS ADL 52 VELCADE melphalan 52 arthrography 52 Meta analyzes 52 c reactive protein 52 noninvasive outpatient 52 PsA 52 inotropic agents 52 cortical atrophy 52 urinary symptoms 52 vitreous haze 52 prespecified 52 neutrophil counts 52 NATRECOR ® 52 baseline A1C 52 SGPT 52 ratio ICER 52 binary restenosis 52 lipid profiles 52 antibiotic rifaximin 52 sonographic examinations 52 VaD 52 nonvertebral fracture 52 antidepressant efficacy 52 recurrent venous thromboembolism 52 IPSS 52 arteriolar 51 angiographic outcomes 51 PCA3 scores 51 tolerability profiles 51 testosterone supplementation 51 serum phosphate 51 creatinine levels 51 dose Iluvien 51 alanine aminotransferase 51 pharmacokinetic equivalence 51 HbA 1c levels 51 Operative mortality 51 platelet reactivity 51 Pharmacodynamic 51 Postoperative 51 serum estradiol 51 venous thromboembolic disease 51 euglycemic clamp 51 Thrombolysis 51 Erythropoietic therapies may 51 deCODE AF TM 51 arterial thickening 51 liver biopsies 51 interobserver agreement 51 parasitemia 51 State Exam MMSE 51 Hazard Ratio HR 51 Functional Assessment 51 Visual acuity 51 RECIST Response Evaluation Criteria 51 intratympanic 51 CIN3 51 Q#IR 51 plasma renin activity 51 weekly subcutaneous injections 51 systolic blood pressures 51 aminotransferase levels 51 neurosensory 51 hemoglobin A1c HbA1c 51 MADRS 51 bronchodilatory 51 Pharmacokinetic parameters 51 NEVO ™ 51 Platelet counts 51 proliferative diabetic retinopathy 51 Score TOS 51 Durezol 51 leukocyte count 51 Reserve Remene Alston 51 perceptual reasoning 51 obstructive coronary artery 51 prognostic indicators 51 advanced neoplasia 51 preclinical efficacy 51 VerifyNow 51 transient elastography 51 #dhTxB# 51 postoperative bleeding 51 hemoglobin A1C 51 donepezil Aricept 51 prospectively evaluated 51 urate levels 51 Pain Rating Scale 51 adjuvant cisplatin 51 % Confidence Interval 51 NCQA accreditation surveys 51 UPDRS Part III 51 juvenile idiopathic arthritis JIA 51 plasma pharmacokinetics 51 zoledronate 51 estimated glomerular filtration 51 FluCAM arm 51 PERMP 51 clinicopathological features 51 autoantibody positive 51 Rating Scale UPDRS 51 serum ALT 51 antigen PSA levels 51 enthesitis 51 CANCIDAS 51 mild renal insufficiency 51 differentiate squamous 51 TNSS 51 gadolinium enhancing 51 Interrater reliability 51 allogeneic HSCT 51 coronary CTA 51 intraoperative complications 51 guaiac 51 hypertension diabetes mellitus 51 fractional shortening 51 thyrotropin levels 51 mmHg diastolic 51 Histological 51 eNO 51 probiotic supplementation 51 isoprostane 51 AUA BPH Symptom Score 51 Global Impression Severity 51 QRS duration 51 subclinical atherosclerosis 51 FOLPI 51 mCRPC 51 ACR# ACR# 51 PCWP 51 affective psychosis 51 Complication rates 51 neuromotor 51 symptomatic paroxysmal AF 51 endocrinologic 51 ionotropic 51 Ejection fraction 51 ovarian malignancy 51 uncorrected visual acuity 51 underwent prostate biopsy 51 cardiopulmonary fitness 51 Avandia Actos 51 weekly CSBMs 51 Baseline characteristics 51 plain radiographs 51 prolongs survival 51 tracer uptake 51 Omiganan 51 radiographic outcomes 51 glycoprotein IIb IIIa inhibitor 51 ADHD RS 51 cardiac autonomic 51 recurrent DVT 51 HBV DNA levels 51 conventional angiography 51 preoperative intraoperative 51 Expanded Disability Status 51 QTc prolongation 51 serum biomarkers 51 cosmesis 51 antidepressants fluoxetine 51 VADT 51 CaPre TM 51 LNG IUS 51 diabetic polyneuropathy 51 hematologic parameters 51 Prostate Specific Antigen PSA 51 submaximal 51 repigmentation 51 cediranib 51 knee osteoarthritis OA 51 intravenous bisphosphonates 51 myocardial uptake 51 SYMBICORT pMDI 51 percutaneous vertebroplasty 51 coronary CT angiography 51 impaired endothelial 51 convergent validity 51 left ventricular systolic 51 pharmacodynamic effects 51 vasomotor 51 SBM frequency 51 BENICAR 51 perfusion MRI 51 histologically confirmed 51 hemoglobin hematocrit 51 de novo coronary 51 mg p = 51 oral rivaroxaban 51 urothelial carcinoma 51 anthropometric measures 51 ETDRS 51 erectile function 51 riociguat 51 variant angina 51 ALT AST 51 nonobese patients 51 psychosocial variables 51 EDSS score 51 multiple logistic regression 51 WOMAC TM 51 glulisine 51 cranial irradiation 51 systolic diastolic 51 Ankle Brachial Index 51 neuropsychological tests 51 oral antidiabetes 51 Glomerular filtration rate 51 nonfatal myocardial infarction MI 51 ejaculatory function 51 Shows Statistically Significant 51 atrophic vaginitis 51 sputum induction 51 lymph node biopsies 51 crizotinib PF # 51 Score DAS# 50 treated nonsurgically 50 FDG PET scans 50 alpha1 antitrypsin deficiency 50 FFR measurements 50 quetiapine Seroquel 50 flurpiridaz F 50 pulmonary arterial 50 inflammatory biomarkers 50 neurocognitive tests 50 Univariate 50 subthalamic 50 venlafaxine XR 50 progestagen 50 squamous intraepithelial lesions 50 HBeAg 50 visceral adiposity 50 suffered perforated bowels 50 serum homocysteine 50 undergoing peritoneal dialysis 50 reduce serum phosphate 50 corneal staining 50 diabetic neuropathy DN 50 diagnosing ADHD 50 pelvic ultrasound 50 lumen diameter 50 airway hyper 50 subclinical disease 50 Cardiac Resynchronization 50 Hormone Refractory Prostate Cancer 50 demonstrated statistically significant 50 T2DM 50 methemoglobin SpMet 50 graft patency 50 Transesophageal 50 neurocognitive impairments 50 esophageal acid 50 mg kg Hematide 50 immunohistochemical 50 binary logistic regression 50 highest tertile 50 SunSpider benchmark 50 ALSFRS R 50 transaminase levels 50 plasma lipids 50 Prognostic significance 50 euthyroid 50 Insulin PH# 50 5 Fluorouracil 50 electroencephalographic 50 serum BDNF 50 fluoroscopy guided 50 meta regression 50 HADS 50 LAB CGRP 50 serum ferritin 50 intravitreal triamcinolone 50 CMV antibodies 50 Mg Usa 50 manometry 50 hypercholesterolemic patients 50 prolactin elevation 50 prolonged QT interval 50 HBeAg seroconversion 50 cromolyn sodium 50 epididymal 50 Cystatin C 50 Mg Uk 50 Post operatively 50 plasma homocysteine 50 aPTT 50 abdominal ultrasound 50 NSTE ACS 50 UPDRS scores 50 spirometric 50 apolipoprotein E4 50 MYCAMINE 50 immunostaining 50 ultrasonographic 50 total cholesterol triglycerides 50 Scale EDSS score 50 mucosal inflammation 50 System IPSS 50 nausea emesis 50 FDA defined valvulopathy 50 interrater reliability 50 histologic subtype 50 T1c 50 hypophosphatemia 50 Score IPSS 50 infarct size 50 glucose homeostasis 50 statistically significant p = 50 GH deficiency 50 hepatorenal syndrome 50 cetrorelix pamoate 50 dose pravastatin 50 nerve conduction velocity NCV 50 hyperreflexia 50 Liver biopsies 50 microsatellite instability 50 bioavailable testosterone 50 LDL HDL 50 multivariable Cox 50 sUA 50 metoprolol tartrate 50 hyperinsulinemic euglycemic clamp 50 clinicopathological 50 transdermal testosterone 50 hawthorn extract 50 arterial oxygen saturation 50 OnDose TM 50 -#.# mg dL [002] 50 visceral metastases 50 Neuropsychological Status 50 Symptom Checklist 50 FSH CTP 50 perioperative complications 50 angiography CTA 50 Zemiva imaging 50 PULMICORT RESPULES 50 experimentally induced 50 PSA kinetics 50 colorectal polyp 50 EDARBI 50 undergone splenectomy 50 statistically significant p 50 clinically insignificant 50 hypoglycaemic episodes 50 hip resurfacing arthroplasty 50 hepatic fat 50 paraprotein 50 transaminase 50 aplindore 50 sociodemographic factors 50 CP CPPS 50 serum prostate 50 alanine transaminase ALT 50 cytological 50 unpaired t 50 hypoglycemic events 50 neurohormonal activation 50 Cronbach alpha 50 multivariate adjustment 50 Echocardiographic 50 preventing genital warts 50 favorable pharmacokinetic profile 50 preterm newborns 50 artery elasticity 50 containing abacavir 50 nucleotide analogue 50 SRBD 50 procalcitonin 50 normal ULN 50 Severity CGI S 50 β blocker 50 leukopenia 50 R entecavir 50 escitalopram Lexapro 50 drugs hydralazine 50 secondary efficacy endpoint 50 amisulpride 50 Insulin sensitivity 50 revealed multivessel coronary 50 CTA# Injection 50 Corus CAD 50 erythropoietic 50 Commonly prescribed 50 Multivariate analyzes 50 Nonspecific 50 EORTC QLQ C# 50 DETROL LA 50 cholestasis 50 underwent surgical resection 50 carotid stenosis 50 Erectile Function IIEF 50 autonomic dysfunction 50 approved incretin mimetic 50 logMAR 49 sulcal 49 statistical significance p 49 Sjögren syndrome 49 intestinal mucosal 49 patients undergoing noncardiac 49 gooey amyloid 49 kidney allograft 49 homocysteine concentrations 49 logistic regression analyzes 49 Intravenous immunoglobulin 49 endometrial biopsy 49 Kruskal Wallis test 49 endometrial ovarian 49 salivary cortisol 49 ASIA Impairment 49 hematological toxicity 49 parkinsonian 49 hypercalciuria 49 beta blocker atenolol 49 aldosterone antagonist 49 HRCT 49 perforated bowels cervixes 49 D dimer 49 PROLARIS 49 CYP#A# CYP#D# 49 heterozygotes 49 Chlamydia trachomatis infection 49 antioxidant supplementation 49 clinico pathological 49 mmol l